Page 4,576«..1020..4,5754,5764,5774,578..4,5904,600..»

Mountain Maladies: Genetic Screening Susses Out Susceptibility to Altitude Sickness

Posted: Published on March 5th, 2014

New tests could spare soldiers from debilitating sickness at high altitudes--and mitigate cattle deaths in the Rockies Chris 73, Wikimedia Commons On his 27th birthday, David Hillebrandt and his wife Sally began to climb Mount Kenya, the second-highest mountain in Africa after Kilimanjaro. Instead of gearing up and heading straight for the mountain's tallest peakwhich reaches 5,199 metersthe couple started their journey more leisurely, trekking through scenic ridges and valleys around the mountain at an altitude of about 3,000 meters. David, who today serves as a medical advisor to the British Mountaineering Council, already had considerable climbing experience at the time: he had scaled a 5,790-meter peak in Pakistan and 3,960-meter peaks in the European Alps. Sally, in contrast, had never done any serious climbing and did not consider herself a mountaineer. But Sally wasn't the one who needed to stop and turn around. "I am meant to be this tough, rugged mountaineer," David says, "and I celebrated my birthday by throwing up all over the place." Plagued by a throbbing headache and relentless nausea, David retreated to lower ground. He knew from previous climbs that he was prone to altitude sickness, but he thought circling the mountain at 3,000 … Continue reading →

Comments Off on Mountain Maladies: Genetic Screening Susses Out Susceptibility to Altitude Sickness

ARGS On The Rise, ATOS Slides After FDA Seeks More Data, XOMA Quits EOA Trial

Posted: Published on March 5th, 2014

By RTT News, March 05, 2014, 12:08:00 AM EDT (RTTNews.com) - Argos Therapeutics Inc. ( ARGS ) touched a new high of $12.55 on Tuesday before closing at $12.30 following new positive findings from a completed phase IIa clinical trial of AGS-004 for the treatment of HIV infection. AGS-004 has been found to induce anti-HIV T memory stem cell-like immune responses in chronic HIV patients and these responses are associated with viral load control in the absence of ART (Antiretroviral Therapy) drugs, said the company. According to the company website, in an ongoing phase IIb clinical trial of AGS-004 enrollment is complete, and results are expected in the second quarter of 2014. Atossa Genetics Inc. ( ATOS ) dropped 11.32% to $1.88 following FDA's request for additional information related to 510(k) application for ForeCYTE Breast Aspirator. The company submitted a Premarket 510(k) Notification with the FDA seeking clearance of the ForeCYTE Breast Aspirator, including the ForeCYTE breast pump and patient collection kit, which are intended for use in the collection of nipple aspirate fluid for laboratory cytological testing last December. Now that the regulatory agency has asked for additional information, Atossa plans to request an extension to the 30 day … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on ARGS On The Rise, ATOS Slides After FDA Seeks More Data, XOMA Quits EOA Trial

Trib Talk: Paying for autism treatment – Video

Posted: Published on March 5th, 2014

Trib Talk: Paying for autism treatment Treatment for autism is expensive and many insurance plans won't cover it. Last year, Utah lawmakers set up a trial "lottery" where 270 children with autism ... By: The Salt Lake Tribune … Continue reading →

Comments Off on Trib Talk: Paying for autism treatment – Video

Autism Treatment: The Most Important Tool to Help Your Child Is You! – The Son-Rise Program – Video

Posted: Published on March 5th, 2014

Autism Treatment: The Most Important Tool to Help Your Child Is You! - The Son-Rise Program http://www.autismtreatment.org/ - Colin and Crystal's teenage son has autism and he wasn't comfortable holding conversations, even with his parents. They att... By: autismtreatment … Continue reading →

Comments Off on Autism Treatment: The Most Important Tool to Help Your Child Is You! – The Son-Rise Program – Video

Spinal-cord crusader hopeful

Posted: Published on March 5th, 2014

Winnipeg Free Press - PRINT EDITION By: Larry Kusch Posted: 03/5/2014 1:00 AM | Comments: It's been four decades since a 15-year-old Rick Hansen was thrown from the back of a pickup truck and suffered a serious spinal-cord injury that would leave him bound to a wheelchair. In that time, Hansen, famous for his Man in Motion World Tour and charitable foundation, has seen great advances in research and treatment that give him hope that someone suffering a similar injury will someday enjoy a better fate. "My belief is -- and the reason I'm engaged in this work -- is to hope that the legacy for the next generation of newly injured... is that they will walk again," he said in Winnipeg Tuesday. Hansen was on hand as the Manitoba government renewed its commitment to funding local spinal-cord research and patient support for another five years. Health Minister Erin Selby said the province would provide $3 million over the next five years. The money continues work that's been going on since 2008. "When I was injured, it took hours for the paramedics to arrive and to medevac me out to a local rural (B.C.) hospital," Hansen said. After several hospital … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Spinal-cord crusader hopeful

tmi196x196.gif

Posted: Published on March 5th, 2014

March 05, 2014 Imagine a future with no sporting events for paralysed people. A future in which there is no need, as all the would-be competitors will have been cured. This scenario, laughable just a few decades ago, is no longer far-fetched, experts say. Bit by bit, important progress is being made in understanding and tackling aspects of paralysis. Some believe the time is fast approaching when the major secondary problems from paralysis bowel, bladder and sexual dysfunction, breathing complications, declining muscle tone and bone density will be treatable, probably through a combination of drugs, cell replacement, physical training and electronic aids. And tentative but encouraging signs are emerging in the quest for the ultimate goal: restoring function to paralysed limbs. "This is an enormously complicated, but we do believe solvable, problem," said Susan Howley, vice-president of research at the New Jersey-based Christopher and Dana Reeve Foundation for paralysis. "Some of the best and brightest people in neurosciences are thinking about spinal cord injury repair, and working on it. There is tremendous hope," she told AFP. Paralysis, full or partial, happens when a message from the brain gets lost on its way to the muscles, blocked by illness or damage … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on tmi196x196.gif

Three-year-old boy dies after new NHS computer system delays heart treatment

Posted: Published on March 5th, 2014

A three-year-old boy died in his parents' arms after a new NHS computer system failed to schedule him for a vital heart scan, a coroner has ruled. Samuel Starr was born with a congenital cardiac defect and needed surgery not long after he was born in 2010. Although he made a good recovery doctors said he would need regular tests to check on his progress. But he did not have a scan until 20 months after his first major operation because of a delay following the introduction of a new computer system, Cerner Millennium. When he finally had the appointment doctors found Samuel needed open heart surgery. During the procedure, Samuel had a stroke. A month later, after further complications, he died in the arms of his devastated parents, Catherine Holley and Paul Starr, at Bristol Royal Hospital for Children. Ms Holley wept as she told the hearing of the moment she kissed her son goodbye, saying: "He was a kind and gentle boy with a great understanding of the world. "As we read Samuel his favourite stories, he died in our arms." Avon Coroner Maria Voisin, recording a narrative conclusion, ruled the booking system meant Samuel was not seen … Continue reading →

Posted in MS Treatment | Comments Off on Three-year-old boy dies after new NHS computer system delays heart treatment

Letters to the Editor for March 4, 2014

Posted: Published on March 5th, 2014

Multiple Sclerosis Awareness Week To the Editor: MS Awareness Week 2014 is March 3 to 9 and people everywhere are creating connections stronger than the ones MS destroys. During this special week, take action to help others learn more about MS and what they can do to make a difference. Multiple Sclerosis is a disease that interrupts the flow of information within the brain and between the brain and the body. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. Here in Northern California MS affects more than 84,000 people. Worldwide, over 2.3 million people live with the unpredictable challenges of multiple sclerosis. The Northern California Chapter of the National MS Society, chartered in 1954, provides comprehensive programs, services and advocacy to assist and empower the more than 84,000 people who are affected by MS annually. The chapter is also a driving force of research for the prevention, treatment and cure of MS and contributes funds to support 350 National MS Society research projects worldwide including almost $12 million in critical MS research initiatives locally at J. David Gladstone Institutes, … Continue reading →

Posted in MS Treatment | Comments Off on Letters to the Editor for March 4, 2014

Personalized Medicine: The New Paradigm in the Prevention and Treatment of Diseases

Posted: Published on March 5th, 2014

(PRWEB) March 05, 2014 In Latin America, Mexico is the pioneer in genetic test applications. Personalized medicine has only been around for the last 15 years. The ALAMPs intention with personalized medicines was to decrease and identify the predisposition of diseases, and to increase the success rate of therapy. A list of international and national guests gathered at this ALAMP sponsored event. Attendees included Stefan Long, director of the science department at General Genetics Corporation, the number one laboratory in the study of ADN in the world; Dr Felipe Vzquez Estupin, specialist in family therapy; and Dr. Bernard Esquivel, president of ALAMP, who discussed the transition that personalized medicine proposes for healthy and sick individuals, as well as for health systems, through the integration of personalized medicine into clinical practice of genetic examinations that strengthen such care. The first international symposium of personalized medicine was directed at any health professional that wanted to incorporate their field in the diverse areas of personalized medicine. This included establishment of the protocols of prevention, follow up and monitoring to the development of specific adequate treatments, and the genetic characteristics of each individual. As defined by the Presidents Council of Advisors of Science and … Continue reading →

Comments Off on Personalized Medicine: The New Paradigm in the Prevention and Treatment of Diseases

Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer

Posted: Published on March 5th, 2014

PUBLIC RELEASE DATE: 3-Mar-2014 Contact: Donna Dubuc donna.M.Dubuc@Dartmouth.edu 603-653-3615 The Geisel School of Medicine at Dartmouth Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small-cell lung cancer, which currently has no effective therapy. The mouse monoclonal antibody they have developed, MAG-1, targets the ProAVP surface marker. When given alone, it significantly slows the growth of tumor xenografts of human recurrent small-cell lung cancer in mice. The study, "Growth Impairment of Small-Cell Cancer by Targeting Pro-Vasopressin with MAG-1 Antibody," was recently published online in Frontiers in Oncology. "We are developing methods of antibody-targeted treatment for recurrent small-cell lung cancer," said lead author William G. North, PhD, professor of Physiology at the Geisel School of Medicine at Dartmouth and a member of the Norris Cotton Cancer Center. "Targeting with a humanized MAG-1 can likely be effective, especially when given in combination with chemotherapy, for treating a deadly disease for which there is no effective therapy." North says his group has already generated a human chimeric form of MAG-1 that is equally effective as mouse MAG-1, and they are now generating a humanized form for use in patients. ### This work was … Continue reading →

Posted in Cell Medicine | Comments Off on Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer

Page 4,576«..1020..4,5754,5764,5774,578..4,5904,600..»